General Discussions

PFS Improves with Ribociclib Use in Younger Women with HR+/HER2- Breast Cancer

By Jason Harris
For the first time, researchers have proven that a CDK4/6 inhibitor is effective in younger, pre- and perimenopausal women with advanced HR-positive/HER2-negative breast cancer. These patients often have few treatment options. But a new study presented at the 2017 San Antonio Breast Cancer Symposium, offers hope. Results of phase 3 of the MONALEESA-7 trial showed that adding ribociclib (Kisqali) to standard endocrine therapy with temporary ovarian suppression significantly improved progression-free survival (PFS) when used as a first-line treatment for this patient group.

The median PFS was 23.8 months for women who received ribociclib in combination with either tamoxifen or a nonsteroidal aromatase inhibitor (AI) and goserelin, a luteinizing hormone-releasing hormone analog, compared with 13.0 months for those who received the standard endocrine therapy plus placebo (hazard ratio [HR], 0.553; 95% CI, 0.441-0.694; P <.0001).1

For patients who received the regimen containing ribociclib and tamoxifen, the median PFS was 22.1 months compared with 11.0 months for the placebo arm (HR, 0.585; 95% CI, 0.387-0.884). Combining ribociclib with an AI resulted in 14-month improvement in median PFS compared with an AI alone (27.5 vs 13.8 months; HR, 0.569; 95% CI, 0.436-0.743).

The overall response rate was 51% versus 36% in favor of the experimental arm. Patient-reported outcomes showed that ribociclib was associated with a statistically significant improvement in time to deterioration, as well as a durable, clinically meaningful reduction in pain score as early as 8 weeks after initiation.

MONALEESA-7 is the first clinical trial to have the statistical power to show that ribociclib is associated with clinical benefit specifically for pre- and perimenopausal women with HR-positive/HER2-negative advanced breast cancer, and the first to show that the CDK4/6 inhibitor is effective in combination with either tamoxifen or a nonsteroidal AI together with ovarian suppression using goserelin, according to lead investigator Debu Tripathy, MD, who discussed the findings during a press briefing. Tripathy is a professor of medicine and chair of the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center.
Start a discussion
You must log in to use this feature, please click here to login.
External Resources

MJH Associates
American Journal of Managed Care
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
OncNurse Resources

Continuing Education
Web Exclusives

About Us
Advisory Board
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2018
Intellisphere, LLC. All Rights Reserved.